scholarly journals Recombinant human growth hormone in the treatment of Turner syndrome

2008 ◽  
Vol Volume 4 ◽  
pp. 1177-1183 ◽  
Author(s):  
Bessie Spiliotis
Keyword(s):  
Growth Hormone ◽  
Turner Syndrome ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth

scholarly journals Evaluation of the results of Turner syndrome patients during the first three years of recombinant human growth hormone therapy

2018 ◽  
Vol 17 (2) ◽  
pp. 75-80
Author(s):  
Wiktoria Osiak ◽  
◽  
Aleksandra Szczepanek ◽  
Beata Branach ◽  
Aleksandra Zimecka ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Turner Syndrome ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth

scholarly journals Long-Term Safety of Recombinant Human Growth Hormone in Turner Syndrome

2008 ◽  
Vol 93 (2) ◽  
pp. 344-351 ◽  
Author(s):  
Katrina Bolar ◽  
Andrew R. Hoffman ◽  
Thomas Maneatis ◽  
Barbara Lippe
Keyword(s):  
Growth Hormone ◽  
Turner Syndrome ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth

scholarly journals Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis

2018 ◽  
Vol 7 (4) ◽  
pp. 573-583 ◽  
Author(s):  
Ping Li ◽  
Fei Cheng ◽  
Lei Xiu
Keyword(s):  
Growth Hormone ◽  
Turner Syndrome ◽  
Human Growth Hormone ◽  
Meta Analysis ◽  
Final Height ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Height Velocity ◽  
Cochrane Central Register ◽  
Rhgh Therapy

Objective This study sought to determine the effect of the recombinant human growth hormone (rhGH) treatment of Turner syndrome (TS) on height outcome. Methods We searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. A literature search identified 640 records. After screening and full-text assessment, 11 records were included in the systematic review. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 software was used for meta-analysis. We also assessed the quality of evidence with the GRADE system. Results Compared with controls, rhGH therapy led to increased final height (MD = 7.22 cm, 95% CI 5.27–9.18, P < 0.001, I2 = 4%; P = 0.18), height standard deviation (HtSDS) (SMD = 1.22, 95% CI 0.88–1.56, P < 0.001, I2 = 49%; P = 0.14) and height velocity (HV) (MD 2.68 cm/year; 95% CI 2.34, 3.02; P < 0.001, I2 = 0%; P = 0.72). There was a small increase in bone age (SMD 0.32 years; 95% CI 0.1, 0.54; P = 0.004, I2 = 73%; P = 0.02) after rhGH therapy for 12 months. What is more, the rhGH/oxandrolone combination therapy suggested greater final height (MD 2.46 cm; 95% CI 0.73, 4.18; P = 0.005, I2 = 32%; P = 0.22), increase and faster HV (SMD 1.67 cm/year; 95% CI 1.03, 2.31; P < 0.03, I2 = 80%; P < 0.001), with no significant increase in HtSDS and bone maturation compared with rhGH therapy alone. Conclusions For TS patients, rhGH alone or with concomitant use of oxandrolone treatment had advantages on final height.

Sign in / Sign up

Export Citation Format

Share Document